Tech Company Financing Transactions
Aura Biosciences Funding Round
Aura Biosciences closed a $3.5 million financing round on 11/3/2017. Investors included private investors.
Transaction Overview
Company Name
Announced On
11/3/2017
Transaction Type
Debt
Amount
$3,537,655
Round
Undisclosed
Investors
Proceeds Purpose
Proceeds purposes were not disclosed. 38 investors participated in the offering. The amount may include options, warrants or other securities. Contact technology company for investment details, if applicable. Not an offer or solicitation for the sale of securities or debt. SEC regulatory filing.
Company Information
Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
85 Bolton St.
Cambridge, MA 02140
USA
Cambridge, MA 02140
USA
Phone
Website
Email Address
Overview
Aura Biosciences is developing a new class of therapies to target and selectively destroy tumor cells. Its lead program in ocular melanoma, developed under a CRADA with the National Cancer Institute (NCI), has been granted orphan drug status by the US Food and Drug Administration.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Elisabet de los Pinos
Chief Financial Officer
Julie Feder
Chief Medical Officer
Cadmus Rich
Browse more venture capital transactions:
Prev: 11/3/2017: Glint venture capital transaction
Next: 11/3/2017: GetYourGuide venture capital transaction
Share this article
Where The Data Comes From
We record all VC transactions involving tech companies. VC investment data records reported here come from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs